Spectrum and frequency of FZD4 mutations in familial exudative vitreoretinopathy by Zhang, Kang & Toomes, Carmel
S p e c t r u m  a n d  F r e q u e n c y  o f  F Z D 4  M u t a t i o n s  i n  F a m i l i a l  
E x u d a t i v e  V i t r e o r e t i n o p a t h y
Carmel Toomes,1 Helen M. Bottomley,1 Sheila Scott, 1 David A. Mackey,1 Jamie E. Craig,2"1' 
Binoy Appukullan,']. Timothy Stout,' Christina J. Flaxel,5 Kang Zhang,6 
Graeme C. M. Black,7 8, Alan Ftyer,9 Louise M. Downey,' and Chris F. Inglehearn1
Purpose. Mutations in the frizzled-4 gene (FZD4) have recently 
been associated with autosomal dominant familial exudative 
vitreoretinopathy (FKVR) in families linking to the HVR1 locus 
on the long arm of chromosome 11. The purpose of this study 
was to screen FZD4 in a panel of 40 patients w ith FKVR to 
identify the types and location of mutations and to calculate 
w hat proportion of this heterogeneous condition is attribut­
able to FZD4 mutations.
Methods. PCR products w ere generated from genomic 1)NA 
w ith primers designed to amplify the coding sequence of 
FZD4. The PCR products w ere screened for mutations by 
single-strand conformational polymorphism-heteroduplex anal­
ysis (SSCP-HA) and by direct sequencing.
Results. In total, eight mutations w ere identified, seven of 
w hich w ere novel. Three w ere deletions (c957delC., 
c 1198dclA. and c l 501-1502delCT), one was a nonsense muta­
tion (Q505X), and four w ere missense mutations (C.361), 
M105T, Ml57V, and S497F).
Conclusions. Fight mutations have been identified in the FZD4 
gene in a cohort of 40 unrelated patients with FFVR. This result 
indicates that FZD4 mutations are responsible for only 20% of 
FFVR index cases and suggests that the other FFVR loci may 
account for more cases than previously anticipated. (In ves t 
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TT'amilial exudative vitreoretinopathy (FFVR) is a well-defined 
X  inherited disorder of retinal vessel development (Online 
Mendelian Inheritance in Man [OMIMJ 133780).1 The disorder 
was first described by Criswick and Schepens in 1969." Since 
then, many more FFVR cases and families have been described, 
and, although its frequency within the population has never 
been calculated, the disorder is thought to be relatively rare. 
FFVR is reported to have a penetrance of 100%, but clinical 
features can be highly variable, even within the same family. 
Severely affected patients may be registered blind during the 
first decade of life, whereas mildly affected individuals may not 
even be aware of symptoms, and in them, the disease is only 
diagnosed by fluorescein angiography.5
The primary pathologic process in FFVR is believed to be a 
premature arrest of retinal angiogenesis-vasculogenesis or ret­
inal vascular differentiation, leading to incomplete vasculariza­
tion of the peripheral retina.1 This failure to vascularize the 
peripheral retina is the unifying feature in all affected individ­
uals, but, by itself, usually causes no clinical symptoms. The 
visual problems and variable phenotype associated w ith FFVR 
result from secondary complications due to retinal ischemia.1 
Leaky abnormal vessels can develop at the edges of the retina 
and can cause subretinal exudation. Furthermore, the neovas­
cularization can regress, leading to the formation of scar tissue 
that produces fractional forces on the retina. These features 
cause a reduction in visual acuity and in 20% of cases can lead 
to partial or total retinal detachm ent.1
FFVR is genetically heterogeneous, w ith X-linked,5'6 auto­
somal dominant,7,s and autosomal recessive9,10 modes of in­
heritance described, autosomal dominant being the most com­
mon m ode.11-15 To date, one X-linked and two autosomal 
dominant loci have been mapped: HVR1 on 11 q ,11 EVR2 on 
Xp,15 And JiVR3  on l i p . 16
The gene underlying X-linked FFVR, EVR2, has been iden­
tified and shown to be the same gene as that mutated in Norrie 
disease (NO).17 Nl) is a rare, X-linked, recessive neurodevelop- 
mental disorder characterized by congenital blindness, with a 
proportion of patients (30%) also having sensorineural deaf­
ness and mental disturbances.ls The Nl) gene encodes a se­
creted protein, N1)P, containing a cystine knot motif.19 How­
ever, the function of N1)P remains elusive, despite the creation 
of a mouse w ith targeted disruption of the gene .20
The autosomal dominant HVR3 gene has been mapped 
within a 14-cM interval on U p l2 -p l3 , defined by markers
C.ATA34F08 (telomeric) and D11S4102 ( c c n tro m c r ic ) .T o  
date, no other HVR3 family has been reported, and the caus­
ative gene remains unknown.
The first FFVR locus to be described was HVR1, which was 
localized to Ilq l3 -q23  in two large Furopean families.11' 1 
Additional linkage studies mapped further families to this re­
gion, 11- 1?--- but none of these families was either informative 
or large enough to refine the disease interval accurately. How­
ever, Robitaille et a l / 5 in 2002 mapped a large Canadian family 
to the HVR1 locus, enabling them to place the disease gene 
within an interval of 1.55 Mb, which contained only two genes. 
Sequencing these genes in this family led to the identification
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T a b le  1 . Sequences of Oligonucleotide Primers Used in the Present Study
Exon Forw ard P rim er 5 '—>3' Reverse P rim er 5 '—*3' Size (bp)
1 CTCCTACCCCCCATCCTC CCATCATCAACTTCCCATCC 396
2a CTCCAACCATTCAACTCACC TTCCTTCCCACACACTCACA 367
2b CTCCCCTTACCTCACAAAACC CACCATATCCTTTCCCCCCC 347
2c CCCCCCATCATATTTCTCAC CACAACCCACTCACTTCATC 374
2d CATCCCCCCACTCAAAACCA CCAATCATCTCCACAATACCC 358
2e CTTCCTCCAACCTCTCTCAT CCCCCCTCACTTAATTCTTC 407
Exon 2 was screened in live overlapping segments designated 2a-2e.
of FZD4 as the defective gene at the F.VR1 locus.'5 The FZD4 
mRNA is 7391 bp long and comprises tw o exons that encode 
the 537-amino-acid protein Frizzled-4.' J Frizzled-f is a member 
of the Frizzled family of seven-pass transmembrane receptors 
that bind Wnt proteins. The Wnt signaling pathway plays a 
major role in differentiation and patterning during embryogen- 
esis and regulates cell proliferation in adult tissues.'5 In addi­
tion, several com ponents of the Wnt signaling cascade are 
implicated in several human cancers.'6 ' 7
In the original study only two FZD4  mutations w ere re­
ported, and both of these w ere deletions found at the C- 
terminal end of the p ro te in .'5 In another recent study, four 
further FBVR mutations w ere identified in a screen of 24 FBVR 
probands, three missense changes, and a nonsense m utation.'x 
The purpose of this study was to  screen this gene in our patient 
cohort to determine further the spectrum and frequency of 
mutations in FZD4  that cause FBVR.
M e t h o d s
Subjects
Genomic DNA samples from 17 FBVR families and 23 single individuals 
with diagnosed FBVR were analyzed in this study. Clinical diagnosis 
was made based on the presence of retinal abnormalities on fundos- 
copy deemed typical of FBVR. These included primarily an area of 
deficient peripheral retinal neovascularization, together with exuda­
tion and/or sequelae of retinal traction, such as macular ectopia, retinal 
folds, and retinal detachment. Fundus fluorescein angiography was 
performed in selected cases to confirm the diagnosis. Informed con­
sent was obtained from all subjects tested, and the research adhered to 
the tenets of the Declaration of Helsinki. Ethical approval was obtained 
from the Leeds Teaching Hospitals Trust Research Ethics Committee 
and the Royal Victorian Eye and Ear Hospital Research and Ethics 
Committee. Control subjects were normal partners of patients attend­
ing the Yorkshire Regional Genetics Department.
Mutation D etection
The coding exons and flanking splice junctions of one affected indi­
vidual from each family were amplified by PCR with the primers 
detailed in Table 1. The method used was the same as that described 
elsewhere.29 Where the single-strand conformational polymorphism- 
heteroduplex analysis (SSCP-HA) showed a mobility shift. PCR ampli­
fication of the coding exon and flanking intronic sequence was per­
formed to provide a template for sequencing. Reactions were 
performed in a 50-fxL volume with 5 0  ng of genomic DNA; 2 0  pmol of 
each primer; 2 0 0  fiM dATP. dCTP. dGTP and d'lTP; 10  mM Tris-IlCl 
(pH 8.3). 5 0  mM KC1; 1 .5  mM MgCl,; 0 .0 1 %  gelatin and 1 unit Taq DNA 
polymerase (Invitrogen Ltd.. Renfrew. UK). After the initial denatur- 
ation step at 96°C for 3 minutes, the samples were processed through 
35 cycles of 94°C for 3 0  seconds. 60°C to 65°C for 3 0  seconds, and 
72°C for 3 0  seconds. A final extension step was performed at 72°C for 
1 0  minutes. Both the forward and reverse strands of the PCR products 
were directly sequenced on a sequencer (Long Read 1R 4 2 0 0 ;  Li-Cor. 
Inc.. Lincoln. NE) using the fluorescence-labeled primer cycle sequenc­
ing kit (Thermo Sequenase; Amersham Pharmacia Biotech. Amersham. 
UK). Sequencing reactions were set up according to the manufactur­
er’s instructions using either the forward or reverse primers detailed in 
Table 1. The nomenclature used to describe the mutations conforms to 
the guidelines established by den Dunnen and Antonarakis.311
A ccession Numbers
Protein sequences for the alignment figure: human Frizzled-4 
NP_036325. Mtis musculus NP_032081. Rattus nort'egictis 
NP_072l45. Gallus galhis Q91A05. Xenoptis laevis Q9PT62. Danio 
rerio NP_57122. human Frizzled-1 NP_003496. human Frizzled-2 
NP_001457. human Frizzled-3 NP_059108. human Frizzled-5 
NP_003459. human Frizzled-6 NP_003497. human Frizzled-? 
NP_003498. human Frizzled-8 NP_114072 (amino acids 151-213 not 
shown in alignment), human Frizzled-9 NP_003499 and human Friz- 
zled-10 NP_009128 (accession numbers from GenBank. http://www. 
ncbi.nlm.nili.gov/Genbank; provided in the public domain by the Na­
tional Center for Biotechnology Information. Bethesda. MD).
R esults
FEVR Patient Screening
To determine the types and frequencies of FZD4  mutations we 
tested 40 unrelated individuals with a clinical diagnosis of 
FBVR. Oligonucleotide primers w ere designed to  amplify both 
the coding exons and flanking splice junctions of FZD4, and 
these w ere analyzed by SSCP-HA and sequencing. Because of 
its large size, exon 2 was amplified in five overlapping seg­
ments (2a-2e). We identified mutations in 8 (20%) of 40 indi­
viduals with FBVR. Bight different mutations w ere found, of 
w hich seven are novel. The characteristics of these mutations 
are presented in Figures 1 and 2 and Table 2.
D eletions
Three different deletions w ere observed that w ere not de­
tected in 200 normal control chromosomes. Mutation screen­
ing in a North American family known to be linked to  the F.VR1 
locus identified a 2-bp deletion in exon 2 (cl501-1502delCT). 
This mutation segregates with the disease and causes a frame­
shift resulting in 32 incorrect amino acids after codon 500 
(NH,_SHVAHVFQQlGHFWKGKHRHHRKWLGHAWKRQ-COOH) 
followed by a prem ature termination at codon 533 
(L501fsX533). This mutation is the same as one reported in the 
original study by Robitaille et a l / 5 It is possible that both these 
mutations w ere found in different branches of the same family 
as both originated from the Unites States, but haplotype anal­
ysis must be performed to  confirm this hypothesis.
Also in exon 2, w e identified a 1-bp deletion, cl498delA, in 
a single British patient w ho had an affected parent that we 
w ere unable to examine. This mutation causes a frameshift 
resulting in the substitution of 12 amino acids after codon 499 
(NH2-LFTRGRSVPTDW-COOH) and a prem ature stop in codon 
512 (T500fsX512).
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Figure 1. (a) F7.D4 mutation c957delG tracking in a family with 
asymptomatic individuals. The figure shows the HA result obtained 
using amplimers 2c and the sequence trace of the mutation containing 
allele and the corresponding wild-type allele. The symbols with dots 
represent asymptomatic individuals, (b) F7.D4 mutation c1513C^>T 
tracking in a family. The figure shows the HA result obtained using 
amplimers 2e and the sequence trace of the mutation containing allele 
and the corresponding wild-type allele. The sequence traces shown in 
(a) and (b) were obtained from cloned PCR products and therefore 
only show one allele, (c) Photograph of the eyes of a severely affected 
member of the family in 1b (indicated by *) demonstrating leukocoria 
(a white mass behind the pupil due to a total retinal detachment).
The third deletion was identified in an Australian patient— 
another 1-bp deletion in exon 2, c957delG. This mutation 
causes a frameshift after codon 3 IB replacing four amino acids 
(W319C, W320G, V321L, and 1322F), before introducing a 
premature stop at codon 323 (W319fsX323). This mutation 
was found in tw o asymptomatic family members: the pro­
band’s father and sibling (Fig. 1 a). It is possible that the 6-year- 
old sibling is presymptomatic, but the father had undergone a 
full examination using slit lamp biomicroscopy and indirect 
ophthalmoscopy in conjunction with mydriatics, and no reti­
nopathy was observed. Nevertheless, because neither of these 
individuals was examined by fluorescein angiography, the only 
accurate clinical method for diagnosing asymptomatic FFVR 
cases, their lack of symptoms is not unexpected.
N onsense Mutations
One nonsense mutation was detected in an Australian family in 
exon 2, Q505X. This change resulted from a C—»T transition in 
the first base of the codon (cl513C^>T), the mutated C being 
part of a highly mutable CpG dinucleotide. The effect of this 
mutation would be a shortened protein of 504 amino acids 
instead of the 537 amino acids found in the wild-type protein. 
This mutation segregates with the disease in this family apart 
from in the patriarch, w ho was asymptomatic (Fig. lb). The 
mutation was not found in 200 normal control chromosomes.
M issense Mutations
Four putative missense mutations w ere identified. In exon 1 
w e identified G361) (cl07G^>A) in a single North American 
patient. In exon 2, w e identified three changes. Ml57V
(c469A^>G) segregates with the disease in a large American 
family known to be linked to MVRI and M105T (c314T ^C ) 
and S497F (c 1490C^>T) w ere identified in tw o British patients, 
each with a family history of FFVR. None of these changes was 
identified in 400 ethnically matched normal chromosomes.
Benign Variants
In addition to  the above mutations, a missense change that was 
not disease specific was detected, P168S (c502C^>T). This 
change appears to  be rare, w ith the serine allele only being 
found once in 200 w hite control individuals, a frequency of 
less than 0.3%. A polymorphism was also identified in the 3' 
untranslated region (UTR), 2 bp after the STOP codon, 
cl616g^>t. The frequency of the t allele was calculated to  be 
2% in whites.
Phenotypic Characteristics in  Patients w ith  
FZD4 Mutations
To assess the range of clinical features associated w ith muta­
tions in FZD4 and to  identify any specific characteristics that 
may be unique in patients with FFVR with mutations in this 
gene, a combination of clinical reexamination and/or inspec­
tion of existing clinical notes was undertaken in the patients 
with FFVR in whom w e had identified FZD4 mutations.
The large North American family with the c 1501-1502delCT 
mutation consisted of 39 members within three generations in 
w hich FFVR was dominantly transmitted to 12 members. All 
affected patients manifested ophthalmic features within the 
first decade of life, and most w ere severely visually disabled by 
the second decade. The youngest affected individual was noted 
at 20 days of age (after a full-term, uncomplicated pregnancy) 
to have temporal dragging of the macula and optic nerve, 
widespread peripheral retinal avascularity, and extraretinal 
neovascularization. Older (untreated) members of this family 
had bilateral cicatrized fractional retinal detachments w ith sub- 
retinal cholesterol crystals and chronic intraretinal exudates. 
No asymptomatic carriers of this mutation w ere identified; 
however, w e examined DNA from only 11 family members and 
only five of these had received a clinical diagnosis as unaf­
fected; thus, the possibility of clinically normal mutation car­
riers cannot be ruled out.
A highly variable phenotype was noted in the Australian 
family with the Q505X mutation. Four mutation-carrying indi­
viduals w ere identified spanning three generations, but in only 
two of these had “Norrie disease/severe FFVR” originally been 
diagnosed. The proband’s maternal uncle (Fig. lb, top, individ­
ual marked w ith an asterisk) had a bilateral total retinal detach­
ment by age 6, resulting in no light perception (Fig. 1c), and 
the proband, w ho was also male, was noted to  have a temporal 
sector of retina with deficient vascularization associated with 
areas of white fibrotic preretinal tissue. However, his mother 
was initially reported to  have only high myopia and myopia- 
associated visual deterioration, as she showed no signs of 
retinopathy, and his grandfather was clinically normal.
The third family studied, harboring the Ml57V mutation, 
also showed a wide spectrum of phenotypes. This U.S. family 
contained 17 members spanning four generations, nine of 
w hich w ere affected. However, in three of these affected 
individuals, FFVR was diagnosed only by fluorescein angiogra­
phy, and they had no clinical problems, whereas other affected 
individuals had a more severe range of phenotypes, including 
macular folds and retinal detachments.
In the Australian patient w ith the c957delG mutation, the 
disorder was diagnosed at 8 months, w ith a peripheral retinal 
fold in the left eye associated with retinal traction. The left eye 
showed areas of preretinal fibrosis, and both eyes showed 
characteristic deficient vascularization of the peripheral retina.
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F ig u r e  2 .  ( a )  Schematic diagram of 
the FZD4 gene and (b) the Frizzled-4 
protein showing the types and loca­
tions of the mutations. The locations 
of the transmembrane domains were 
derived from entry Q9ULV1 in Gen- 
Bank.
Aged 4 at the time of this report, the patient had poor visual 
acuity (Ol) —6/48 and OS —2/60). On molecular testing, his 
brother and father w ere found to be carriers of this mutation, 
but both are emmetropic and appear clinically normal (Fig. la).
The British patient with the M105T mutation had a known 
family history of FKVR. Her sister was severely affected, result­
ing in partial blindness and her niece (the sister's child) was 
blind from a very young age, due to  bilateral retinal detach­
ment. The patient presented to  the clinic as an emergency case
with a left macula-off rhegmatogenous retinal detachment 
w hich was successfully repaired. Further examination identi­
fied inadequate vascularization of the peripheral temporal ret­
ina. She currently has visual acuity of Ol) —6/9 and OS —6/ 
12-1.
The British patient with the c 1498delA mutation was noted 
to have very little vision (hand movements only) in the left eye. 
This eye was microphthalmic w ith evidence of posterior len- 
ticonus with lens opacity, a degenerative vitreous with a band
T a b u  2 . Summary of Mutations Found in FZD4 to Date
Exon
Amplimers cDNA Change Protein Change Family/Single
Family
History Freq. Reference
1 cl07G—*A G36D Single No 1 Present study
2(a) c313A—*G M105V Family Yes 1 28
2(a) c314T—>C M105T Single Yes 1 Present study
2(a) cl69A—>G M157V Family Yes 1 Present study
2(c) c957delG W319fsX323 Family Yes 1 Present study
2(c) c957G—*A W319X Single No 1 28
2(d) c 1250G—>A R417Q Family Yes 28
2(e) cll63G —>A G488D Family Yes 1 28
2(e) cl490C—>T S497F Single No 1 Present studv
2(e) cl479-1484delGTGGAT M493-W494del Family Yes 1 23
2(e) cl498delA T500fsX512 Single Yes 1 Present study
2(e) c 1501-1502delCT L501fsX533 Family Yes 2 Present study and 23
2(e) cl513C^>T Q505X Family Yes 1 Present study
Amino acid and nucleotide numbering follows the cDNA sequence (Accession no. NM_012193). with nucleotide position 1 assigned to the 
first nucleotide of the ATG initiation codon in exon 1. Family indicates that the mutation segregated in other family members. Single indicates that 
the mutation was found in a single patient for whom no further family DNAs were available. Freq.. frequency.
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extending from a small pale optic disc head with extensive 
chorioretinal mottling and attenuated retinal vasculature. The 
right eye was highly myopic with some cortical lens opacities. 
The vitreous was degenerative with a small myopic optic disc 
and diffuse nonspecific pigmentary changes in the retina. The 
patient’s father was mildly affected but able to drive. He had 
undergone childhood surgery for strabismus and had an am­
blyopic left eye. Detailed examination of his left eye was 
difficult because of lens opacities, but he had some linear 
circumferential vitreous opacities with areas of fractional reti­
nal detachment and subretinal exudation.
The British patient with the S497F mutation was noted to 
have the classic features of FKVR. She had disc-dragging in both 
eyes and localized retinal elevation temporally in both eyes 
with hemorrhage and gliosis. Exudation was present temporal 
to the left fovea. Her mother had dragged discs, and temporal 
sectors of pigment change typical of FKVR.
Unfortunately, we w ere unable to obtain detailed clinical 
notes for the patient w ith the C.36D mutation, and so the 
severity of this patient’s phenotype is unknown. Notes state 
that the patient had no family history of FFVR but only the 
mother’s DNA was tested for the mutation.
D isc u ssio n
We screened 40 unrelated patients w ith FFVR to determine the 
types and frequencies of mutations in FZD4  and identified 
eight different disease-causing mutations. Four of these muta­
tions are predicted to result in truncation of the mRNA, with 
the proportion of the mRNA deleted ranging from 40% for the 
c957delC, deletion to 1% for the cl 501-1502delCT deletion. 
Although the most likely outcome for mutations resulting in 
premature termination codons (PTC) is haploinsufficiency 
caused by nonsense-mediated mRNA decay, this is not always 
the case if the PTC is not followed by a downstream intron. ' 1 
All the truncating mutations identified in FZD4  are located 
within the large last exon, and it is therefore possible that these 
mutations result in the production of a truncated protein. 
Further experiments are needed to determine w hether this is 
indeed the case.
The remaining mutations identified w ere substitutions alter­
ing amino acids. It is more difficult to determine with absolute 
certainty w hether these mutations are disease causing, al­
though the identification of a second point mutation affecting 
amino acid 105 in an FFVR family adds strength to the pro­
posed pathogenic nature of the M105T m u ta t io n .T h e  defi­
nition of a polymorphism is any genetic variant w here the 
frequency of the rarer allele is greater than 1 %. We excluded 
each of these changes in 400 normal ethnically matched con­
trol chromosomes, indicating with over 95% confidence that 
the frequency of these changes is less than 1%, providing 
supportive data that these are disease-causing mutations, rather 
than rare polymorphisms.32 Furthermore, w e checked each of 
the amino acids changed for conservation within l ri//lcd- i 
proteins from other species and also within other members of 
the human Frizzled protein family (Fig. 3). All the missense 
changes are nonconservative substitutions, w ith the exception 
of M157V, but the valine residue at this position was not seen 
in any of the homologues (Fig. 2). All the residues changed are 
well conserved among the orthologues with the exception of 
/cbrafish I ri/zlcd- i. which has different amino acids for three 
of the four mutations. The conservation of the changed amino 
acids within the paralogues is less convincing, with only the 
serine at codon 497 being highly conserved (Fig. 3).
Frizzled-4 contains a signal peptide in its N terminus, direct­
ing it to the plasma membrane, which is cleaved off after its 





































































































GPA----------- RGFG- -DEEERR--- CDPIRISMC 53
RPT----------- L6FG- -DEEERR--- CDPIRIAMC 53
RPA----------- LGFG- -DEEERR--- CDPIRIAMC 64
$Gi|--------------- H R —M i -----jjpnTttTAiar 41
GLI----------- AGFG- -EEEERS--- CDPIRITMC 39
DPD----------- R----- PGEGR----CQEIAIPLC 43
----------- RQIS--VPDHGY--- CQPISIPLC 124
AAGPAQFHGE---- KGIS--IPDHGF----CQPISIPLC 47
--- Iepitlriic 36
--G----------- RAAA--ASKAPV--- CQEITVPMC 41
-------- CEPIXVPRC 32
ALSAGAGAQPYHGEKGIS--VPDHGF--- CQPISIPLC 57
SSG----------- AAAA--SAKELA--- CQEITVPLC 43













ANLECS PNIETFLCKAFVPTCIEQIHV-VPPCRKLCEKVY 103 
VKVQCSPELRFFLCSMYAPVCT-VLDQAIPPCRSLCERAR 128 
VEIQCSPDLKFFLCSMYTPICLEDYKKPLPPCRSVCERAK 115 


































148 re-------- P-QNDHNHMCMEGP— GOBI--
149 re-------- P-QNDHNHMCMEGP--GDEE--
136 If-------- P-QNDHNHMCMEGP--GDE*---






138 LP-------- N-KNDPNYLCMEAPNNGTDE------- P 159
218 Pf-------- V-HGAGELCVGQNT--SDKG------- T 237
141 FP-------- R-HGAEQICVGQNH--SEDG--------A 160
130 Yt--------------------------DCD--------E 135
136 LP-------- VLGRDAEVLCMDYN- -RSEA--------T 156
126 L---------------- QYC-------DET--------V 133
151 FPVHGAGEICVG-QNTSDGSGGPGG- -GPTA------- Y 179
138 LP-------- E-QGNPDTLCMDGG--GKAR--------P 157
142 Li-------- T-RNDPHALCMEAP— ENAT--------A 161




479 MLKIFMSLLVGITSGMWIWSAKTLHTWQKCSNRLVNSGKV 518 
466 MLKIFMSLLVGITSGMWIWSAKTLHTWQKCSNRLVNSGKV 505 
464 MLNIFMSLLVGITSGMWIWSAKTLHTWQKCTNRLVNSGKV 503 
504 MVKIFMLLWGITSGMWIWTSKTLQSWQ 531 
604 MIKYLMTLIVGITSGFWIWSGKTLNSWRKFYTRLTNS 640 
622 MIKYLMTLIVGITSGFWIWSGKTLHSWRKFYTRLTNS 558 
481 LMKYLMALIVGIPSVFWVGSKKTCFEW 507
504 MLKYFMCLWGITSGVWIWSGKTVESWRRFTSR 536 
477 MIKYLMTLIVGISAVFWVGSKKTCTEtf 503 
531 MIKYLMTMIVGITTGFWIWSGKTLQSWRRFYHRLSHSSK 569 
587 MLKYFMCLWGITSGVWVWSGKTLESWRSLCTR 619 
511 MLKIFMSLWGITSGVWVWSSKTFQTWQSLCYRKIAAGRA 550
505 MVKIFMLLWGITSGMWIWTSKTLQSWQQ 533
F ig u r e  3- Protein sequence alignment of human Frizzled-4 with ho­
mologues from human and other species: mouse, rat, chick, frog, and 
zebrafish Frizzled-4 proteins and the human Frizzled family of proteins. 
Only 20 amino acid residues surrounding each mutation are shown. 
Conserved amino acid residues are highlighted. The positions of the 
missense mutations G36D, M105T, Ml 57V, and S497F are indicated.
The location of this cleavage site is predicted to be between 
amino acids 36 and 37 by two signal peptide prediction pro­
grams, PSORT (Predication of Protein Sorting Signals and 
Localization Sites in  Amino Acid Sequences; http ://psort.
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nibb.ac.jp/ coded by Kenta Nakai, Human Genome Center, 
Institute for Medical Science, University of Tokyo, Japan) and 
SignalP (http://www.cbs.dtu.dk/services/SignalP-2.0/ provided 
in the public domain by the Center for Biological Sequence 
Analysis, Technical University of Denmark, Lyngby, Denmark). 
This is the precise location of the C.36D mutation, and it is 
likely that this change affects the cleavage of the mature pro­
tein.
Two of the missense changes (M105T and M157V) are 
located within the extracellular cysteine-rich domain (CRD) of 
l ri//lcd-i. All Frizzled receptors have an extracellular CRD 
with 10 invariant cysteines, and this is reported to be the 
binding site for the W nt proteins.”  Although the sequence 
similarity of the CRD differs significantly between Frizzled 
receptors (ranging from 30% to 50% overall identity; Fig. 3),31 
they adopt the same three-dimensional crystal structure be­
cause of the conserved cysteines/5 The remaining variability 
between the 10 human Frizzled receptor CRDs is thought to 
underlie their different Wnt binding specificities. This may 
explain why the mutated residues in the CRD are highly con­
served among orthologues but less so between the other hu­
man Frizzled receptors (Fig. 3).
More detailed studies have been perform ed to determine 
which regions within the CRD are critical for W nt b in d in g /5 In 
vitro binding assays, which exploit the high binding affinity of 
X e n o p u s  Wnt8 to the CRDs of D rosophila  Frizzled-2 and mu­
rine Frizzled-8, allowed Dann et a l / 5 to mutate different re­
gions of the CRDs and to determine what effect the mutations 
had on W nt binding. Although none of the mutations created 
were the same as those found in this study, Dann et al. created 
a map highlighting the specific segments of the CRD surface 
important for Wnt binding. Given the homologous structure 
and function of the Frizzled CRD, it is assumed that all Frizzled 
CRDs bind Wnt proteins in a conserved fashion.55 We there­
fore used the Cn3D 4.1 software available from the National 
Center for Biotechnology Information (NCBl; Bethesda, MD) to 
align the protein sequence of the Frizzled-4 CRD with the 
crystal structure of mouse Frizzled-8 CRD (11JY-A) (h ttp :// 
www.ncbi.nlm.nih.gov/Structure/CN3D/cn3d.shtml). This analy­
sis showed that both the M105T and M157V mutations are 
likely to be located in the region of the CRD surface most 
strongly implicated in W nt binding by Dann et al.
Furthermore, while determining the crystal structure for 
the CRD of Frizzled proteins, Dann et a l / 5 found evidence that 
mouse Frizzled-8 and secreted Frizzled-related protein 3 form 
homodimers, and they mapped the dimer interface surface. 
Although this initial observation was only tentative, a further 
study has confirmed that X en o p u s  Frizzled-3 forms ho­
modimers when overexpressed in X en o p u s  embryos.56 How­
ever, dimerization is not a characteristic of all Frizzled recep­
tors as the same study showed that X en o p u s  Frizzled-7 remains 
monomeric.56 W hether Frizzled-4 undergoes dimerization has 
not been investigated and remains undetermined, but the 
M157V mutation is located within Frizzled-4s putative dimer 
interface surface raising the possibility that it may interfere 
with W nt binding by hindering CRD dimerization.55
The S497F mutation occurs at a highly conserved residue 
located at the beginning of the C-terminal cytoplasmic tail, 
directly adjacent to the conserved Lys-Thr-X-X-X-Trp motif 
which is required for the activation of the Wnt/j3-catenin path­
way and for membrane relocalization and phosphorylation of 
Dishevelled.51 It is therefore likely that this residue is of func­
tional importance. Although the pathogenic effects of all these 
missense mutations have not been proven, these data suggest 
that they are likely to be pathogenic.
There are now a total of 13 different mutations reported to 
cause FEVR (Table 2), including four deletions, seven missense 
and two nonsense mutations. The location of these mutations
suggests that they result in loss of function of Frizzled-4. Seven 
of these mutations are predicted to alter the C-terminal cyto­
plasmic tail of Frizzled-4 which is crucial in all three of the 
signaling pathways that Frizzled receptors use to transduce 
their signal; the canonical Wnt/j3-catenin pathway,57 the W nt/ 
Ca2+ pathway5*5 and the planar cell polarity (JUN) pathway59 
(Fig. 2b). Similarly, four of the missense mutations are in 
functional sites in the extracellular domain, three located 
within the CRD and one located at the signal peptide cleavage 
site.
Only one mutation was found in the N terminus of Friz- 
zled-4 (C.36D). Apart from its effect on Frizzled-4, this mutation 
could also alter a putative second transcript reported to be 
encoded by FZD4 designated SFZD 4.io. This splice variant 
retains the intron between exon 1 and 2 of FZD4 and is 
reported to encode a soluble polypeptide of only 125 amino 
acid residues due to the presence of a stop codon within the 
retained intron. The first 98 amino acids are identical with 
Frizzled-4 and encode the first half of the CRD but the last 27 
residues are unique.1” A family of five secreted Frizzled-related 
proteins (SFRP1-SFRP5) have been described; they contain the 
full CRD and act as W nt antagonists but are encoded by distinct 
genes and are not splice variants of Frizzled receptor genes.11 
Sagara et al.1” performed a number of X en o p u s  embryo injec­
tions with SFZD4 and suggested that it functions as a positive 
regulator of the Wnt signaling pathway. However, this variant 
has only been described in a single study and although the 
authors checked that the transcript was not due to genomic 
contamination of their cDNA, they did not rule out the possi­
bility of contaminating heterogeneous nuclear RNA. Further­
more, no similar splice variants have been identified for the 
remaining nine Frizzled proteins. As the expression of SFZD4 
is not supported by other experimental evidence, its existence 
is still tentative and further studies are required.
We identified FZD4 mutations in 20% of our index patients 
(8/40). Similarly, the original study by Robitaille et a l / 5 iden­
tified two mutations in five autosomal dominant FHVR families 
and the study by Kondo et al/*5 identified five mutations in a 
panel of 24 probands screened. Detection rates of 20% to 40% 
were unexpected as EVR1 was always thought to be the major 
autosomal dominant FHVR locus, based on the results of a 
series of linkage studies that report EVR1 linked pedigrees.11 
i L22 It is possible to speculate that this low detection figure 
may be due to a proportion of our patients’ harboring muta­
tions within the ND gene or in an unidentified recessive FHVR 
gene, especially in those patients without a family history. 
However, we found only FZD4 mutations in 6 (35%) of our 17 
families, each of w hich had a clear pattern of autosomal dom­
inant inheritance. Furthermore, of the 21 single patients in 
whom we failed to find an FZD4 mutation, 7 were females and 
10 of the males had already tested negative for ND gene 
mutations, leaving only 4 males for whom a diagnosis of X- 
linked FHVR could not be ruled out. We anticipate that a few 
mutations may have been missed by the mutation detection 
method used in this study. Similarly, large rearrangements or 
deletions within the gene have not been examined and the 
promoters, introns, and the 5'- and 3'UTRs have also not been 
screened. However, it is more likely that the low mutation 
detection rate obtained in all three studies is due to autosomal 
dominant FHVR’s being more heterogeneous than previously 
thought.
Confirmation of this theory has recently been provided by 
the discovery of a new autosomal dominant locus adjacent to 
FZD 4.l2. By performing high-resolution genotyping in a large 
Asian family originally linked to the EVR1 locus by Price et 
a l . /2 we were able to genetically exclude FZD4 as the mutated 
gene in this family and consequently identified a third autoso­
mal dominant FHVR locus, designated E V R 4 .12 This new locus
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is positioned only 10-ciM centromeric to FZD4 and spans a 
15-cM interval flanked by the markers D11S1368 and 
D11S937.12 The occurrence of two FKVR loci within such 
close proximity provides a likely explanation as to why Kondo 
et al.28 could find only FZD4 mutations in 3 of their 11 families 
reportedly showing linkage to F.VR1. Similarly, it is now pos­
sible to speculate that the reason F.VR1 was always reported as 
the major FKVR locus was because there w ere in fact two 
neighboring loci in this chromosomal region. However, the 
original linkage studies reporting F.VR1 linked families were 
perform ed before the identification o f F.VR3, and, as a result, 
many laboratories perform ed their analysis on the assumption 
that autosomal dominant FFVR was homogeneous. By reana­
lyzing the available data from these studies it is now evident 
that no one major FFVR locus exists.12 In light of this reap­
praisal, the identification o fF.VR3lh a n d F.VR4'1 and evidence 
for further locus heterogeneity,15 the low frequency of FZD4 
mutations identified in this and other studies25,28 suggests that 
the remaining patients most likely harbor changes in other, as 
yet unidentified, FFVR genes.
The clinical features present in most of our FZD4 patients 
with FFVR fit well w ith classic descriptions of FFVR1 and with 
the phenotypes seen in families linking to other FFVR 
loci.16,l2~15 The one exception to this is a patient w ith the 
cl498delA mutation. Along with features typical of FFVR, this 
individual also has characteristics suggestive of additional dis­
ease; however, these features were not seen in a second family 
member w ho has features consistent w ith an FFVR diagnosis. 
As a consequence, we were not able to identify any distinguish­
ing features specific to FZD4-¥VN% nor were we able to see 
any genotype-phenotype correlation between the different 
mutations observed, although this was not unexpected as 
widely varying phenotypes are often seen within the same 
family. It is interesting to speculate why these patients with 
FFVR have defects only in the development of the retinal 
vasculature when FZD4 is widely expressed throughout the 
body.21 This may indicate redundancy of Frizzled-4 function in 
other tissues, most likely as a result of the other nine human 
Frizzled genes compensating for the loss. However, it may also 
be that the development of the retinal vasculature is the only 
process limited by the amount of Frizzled-4 protein available 
and as a result is the only tissue affected by the Frizzled-4 
haploinsufficiency observed in FFVR.
This study offers insights into the type, distribution, and 
frequency of FZD4 mutations that cause FFVR. Continued 
identification of mutations will allow accurate diagnosis of 
asymptomatic individuals, avoiding in some cases the need for 
fluorescein angiography (which is not w ithout complications) 
and will perm it better genetic counseling of patients. This 
study also provides evidence that autosomal dominant FFVR is 
more heterogeneous than previously thought and strongly sug­
gests that further loci remain to be identified.
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